Chemotherapy· 2017Q3
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
- 2,333citations
- Q3SCImago
- 2017year
Short summary
Single-agent pixantrone induced remission in a patient with diffuse large B-cell lymphoma refractory to multiple prior chemotherapy regimens, successfully bridging them to autologous stem cell transplantation.
AI-generated from the title and abstract; the full text is not read.
Key points
- Pixantrone achieved remission in a patient with diffuse large B-cell lymphoma refractory to R-CHOP and R-DHAP.
- The patient successfully underwent autologous stem cell transplantation after pixantrone treatment.
- Continuous complete remission was maintained for 20 months post-transplant.
- Pixantrone was well-tolerated with no serious side effects reported.
AI-generated from the title and abstract; the full text is not read.
Abstract
Aggressive non-Hodgkin lymphoma is associated with poor long-term survival after relapse or resistance to chemotherapy. We report a case of aggressive non-Hodgkin lymphoma refractory to first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and second-line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) chemotherapy treatments. The patient achieved remission with single-agent pixantrone, and received a consolidation with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) chemotherapy and autologous stem cell transplantation. He received consolidation radiotherapy on the site of bulky disease. At 20 months from transplant, the disease is in continuous complete remission. The successful use of pixantrone as a bridge to transplant is highlighted, together with the absence of serious side effects.
The authors' abstract, as published at the source. Chemotherapy, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine